Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit Portfolio News / By Karina Tin October 26, 2022 Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit Read More »
eFFECTOR Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotaifin for the Treatment of Covid-19 Portfolio News / By Karina Tin October 26, 2022 eFFECTOR Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotaifin for the Treatment of Covid-19 Read More »
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 Portfolio News / By Karina Tin October 17, 2022 NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 Read More »
Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases Portfolio News / By Karina Tin October 6, 2022 Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases Read More »
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin October 6, 2022 Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update Read More »
